An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 11, 2008, Pages 1068-1076

  Colman, Eric ^a   Szarfman, Ana ^a   Wyeth, Jo ^a   Mosholder, Andrew ^a   Jillapalli, Devanand ^a   Levine, Jonathan ^a   Avigan, Mark ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

AERS; Amyotrophic lateral sclerosis; Data mining; Statins

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BULBAR PARALYSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA MINING; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHAGIA; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; MUSCLE CRAMP; MUSCLE WEAKNESS; NEWBORN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SLURRED SPEECH; TREATMENT DURATION; UNITED STATES;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ALGORITHMS; AMYOTROPHIC LATERAL SCLEROSIS; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 57649218663     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1643     Document Type: Article

References (41)

1. National Cholesterol Education Program (US). The third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol (adult treatment panel III). National heart, lung, and blood institute (US) [Internet], 2002 [cited 6 June 2007]; (NIH publication: no. 02-5215): 1-284. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3_rpt.htm
2. Vector One®: National [electronic database]. Yardley (PA): Verispan, LLC. Years 2002-2006.
3. Bruckert E, Hauem G, Dejager S. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO Study. Cardiovasc Drugs Ther 2005; 19: 403-414.
4. Thompson PD, Clarkson PM, Rosenson RS. The national lipid association statin safety task force muscle safety expert panel. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97(8A): 69C-76C.
5. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-408.
6. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52: 39-59.
7. Brooks BR, Miller RG, Swash M, Munsat TL. World federation of neurology research group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(5): 293-299.
8. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002; 59(2): 280-282.
9. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031-2041.
10. Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing 2004; 33(2): 131-134.
11. Edwards RI, Star K, Kiuru A. Statins, neuromuscular degenerative disease, and an amyotrophic lateral sclerosis-like syndrome. Drug Saf 2007; 30: 515-525.
12. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005; 28(11): 981-1007.
13. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53(3): 177-190.
14. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25(6): 381-392.
15. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007; 82 (2): 157-166.
16. Szarfman A, Tonning JM, Doraiswamy PM. Pharmaovigilance in the 21st century: new systematic tools for an old problem [editorial]. Pharmacotherapy 2004; 24(9): 1099-1104.
17. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf 2005; 28(11): 981-1007.
18. El Escorial world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/ amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994; 124: 96-107.
19. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 1991; 48(6): 589-593.
20. McGuire V, Longstreth WT Jr, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 1996; 47(2): 571-573.
21. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23: 871-880.
22. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006; 26: 1190-1192.
23. King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003; 23: 1663-1667.
24. Padala K, Padala P, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006; 40: 1880-1883.
25. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 2004; 24: 1194-1203.
26. Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006; 97: 86C-88C.
27. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-408.
28. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hyroxy-3-methylglutaryl coenzyme A reducase inhibitors. Pharm Res 1994; 11: 305-311.
29. Kikuchi R, Kusuhara H, Abe T, Endou H, Sugiyama Y. Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J Pharmacol Exp Ther 2004; 311: 1147-1153.
30. Lindberg C, Crisby M, Winblad B, Schultzerg M. Effects of statins on microglia. J Neurosci Res 2005; 82: 10-19.
31. Pahan K, Sheikh FG, Namboodiri AMS, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 11: 2671-2679.
32. http://www.methodisthealth.com/tmhs/newsItem.do?channe1Id= -1073829366&contentId=1073905991&contentType=NEWS_CONTENT_TYPE [Accessed 10 November 2007].
33. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; [b 70 b]: 1004-1009. Epub 16 January 2008.
34. Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 2008; 7: 1-6.
35. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006; 166: 1519-1524.
36. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34(2): 153-162.
37. Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked y simvastatin. Muscle Nerve 2006; [b 34 b]: 478-481.
38. Torbergesen T. Rippling muscle disease: a review. Muscle Nerve 2002; 11: S103-S107.
39. Purvin V, Kawasaki A, Smith K, Kesler A. Statin-associated myasthenia gravis. Medicine 2006; 85: 82-85.
40. Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB. Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 2005; 25: 144-152.
41. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.